Cambridge Healthtech Institute’s 4th Annual
Neoantigen Targeted Therapies
Personalized Cancer Immunotherapy in the Genomic Era
August 8-9, 2019
Fueled with advances in genomic technologies, personalized oncology promises to innovate cancer therapy and target previously undruggable space. Developments in NGS technology enabled systematic analysis of patient-specific mutanome and opens the door
to developing personalized cancer vaccines and other therapies targeting neoantigens. Cambridge Healthtech Institute’s Fourth Annual Neoantigen Targeted Therapies conference brings together thought leaders from pharmaceutical and biotech companies,
leading academic teams and clinical immuno-oncologists to share research and case studies in implementing patient-centric approaches to using the immune system to beat cancer, including utilizing NGS to identify tumor-specific neoantigens, using in silico tools
to predict immunogenic neoepitopes, and targeting them with personalized vaccines, novel antibodies or combination therapies.
Preliminary First-in-Human Data with a Novel MAB, NEO 201, Targeting a Novel Neoantigen in Solid Tumors
Philip Arlen, MD, President & CEO, Precision Biologics
How to Identify a Good Tumor Rejection Mediating Neoepitope
Pramod Srivastava, MD, PhD, Director, Carole and Ray Neag Comprehensive Cancer Center & Professor of Immunology and Medicine, University of Connecticut School of Medicine
Driving T Cell Responses to Neoantigens - the Importance of Priming and Accurate Target Selection
Andrew Allen, MD, PhD, President and CEO, Gritstone Oncology
Th17 T Helper Cell Vaccines for Treatment and Prevention of Cancer
Keith Knutson, PhD, Professor, Immunology; Director, Immunology & Immunotherapy Program, Mayo Clinic
Key Learnings from Bringing a Fully Personalized Cancer Neoantigen Vaccine into the Clinic
Agnete Fredriksen, PhD, CSO, Vaccibody
Personalizing Cancer Vaccines by Pairing Off-the-Shelf Strategies with Optimal Patient Selection
Christopher R. Heery, MD, CMO, Bavarian Nordic
Immunogenic Intensification – an Emerging Strategy to Enhance Cancer Immunotherapy
Marijo Bilusic, MD, PhD, Associate Research Physician, Program Director, NIH Hematology Oncology Fellowship, National Cancer Institute, National Institutes of Health
Big pharma, biotech and medtech need to act to capitalize new innovations that provide solutions to the global demands in healthcare. This insider panel will discuss their areas of interest for in-licensing novel therapeutics, devices and diagnostics
and what they look for in a partner or investment.
Panelists: Michael Woo, MBA, Head, Search & Evaluation, Immuno-Oncology, Business Development & Licensing, Novartis Institutes for BioMedical Research, Inc.
Kathryn McCabe, PhD, Senior Director, Business Development, Emerging Technology and Innovation, Eli Lilly and Company
Scott M. DeWire, PhD, Global Head, Business Development and Licensing, Cancer Immunology, Boehringer Ingelheim Pharmaceuticals, Inc.
For more details on the conference, please contact:
Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute
Email: juliab@healthtech.com
For partnering and sponsorship information, please contact:
Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-247-6286
Email: reymael@healthtech.com